SEC Form 4 · accession 0001209191-16-104240
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael E Porter
Director
Period of report
Feb 29, 2016
Accepted (ET)
Mar 2, 2016 · 11:13 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 29, 2016 | P | 10,000 | $5.61 | A | 709,448 | D | |
| Common StockF2 | Mar 1, 2016 | P | 10,000 | $6.60 | A | 719,448 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.60 to $5.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.46 to $6.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.